{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '6.1.2.7.2 Tumor Imaging During the Study', 'On-study imaging will be performed every 3 months (q3mo. 2 weeks) starting from the day', 'of randomization and regardless of treatment cycle time points (Arm A) for the first two years', 'after randomization and every 6 months (q6mo. 1 months) thereafter calculated from the', 'date of the last imaging, respectively. Imaging can be performed more frequently if clinically', 'indicated and complemented with ultrasound assessments in the intervals if indicated by the', 'judgement of the investigator. Imaging timing should follow calendar days and should not be', 'adjusted for delays in cycle starts (Arm A). Imaging should continue to be performed until', 'relapse is identified by the Investigator or the patients has been observed for at least 5 years', 'after randomization.', '6.1.2.7.3 End of Treatment and Follow-up Tumor Imaging', 'In participants who discontinue study intervention without documented disease progression,', 'every effort should be made to continue monitoring their disease status by tumor imaging every', '3 months (q3mo. 2 weeks) within the first two years after randomization and every 6 months', '(q6mo. 1 months) thereafter to monitor disease status until disease progression, death,', 'withdrawal of consent, or the end of the study, whichever occurs first.', '6.1.2.7.4 Radiologic Assessment of Disease', 'Tumor images will be assessed by the local investigator for tumor relapse. The individual', 'judgement of the investigator will serve as the basis for all protocol guidelines related to', 'disease status (e.g. continuation or discontinuation of study intervention).', '6.1.2.8 Covid-19 policy', 'Assessment of Covid-19 should be conducted according to the actual pandemic situation AND', 'institutional policy that is applied to any patient that receives FOLFOX/FOLFOXIRI for', 'colorectal cancer outside the trial. This may require assessment of vaccination status, physical', 'examination, anamnesis and Covid-19 tests (e.g. antigen test and/or PCR testing). SARS-', 'CoV-2-positive (without exceptions no matter if symptomatic or without symptoms) patients', 'should not participate in the trial or chemotherapy application should be delayed as long as', 'the patient is positive for SARS-CoV-2. Respective assessments should be repeated at any', 'time if the investigator judgement, particularly in cases that present with new or changed risk', 'factors (efficacy of vaccines, contact with infected patients etc).', '6.1.3 Clinical Safety Laboratory Procedures/Assessments', 'Details regarding specific laboratory procedures/assessments to be performed in this trial are', 'provided below and timing and frequency is specified in the Schedule of Trial Activities (Section', '2.3).', 'Confidential', 'Page 46 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'The investigator or medically qualified designee (consistent with local requirements) must', 'review the laboratory report, document this review, and record any clinically relevant', 'changes occurring during the study in the AE section of the eCRF. The laboratory reports', 'must be filed with the source documents. Clinically significant abnormal laboratory findings', 'are those which are not associated with the underlying disease, unless judged by the', \"investigator to be more severe than expected for the participant's condition.\", 'If laboratory values from non protocol-specified laboratory assessments performed at the', \"institution's local laboratory require a change in study participant management or are\", 'considered clinically significant by the investigator (e.g. SAE or AE or dose modification),', 'then the results must be recorded on the appropriate eCRF page.', 'For any laboratory tests with values considered clinically significantly abnormal during', 'participation in the study or within 30 after the last dose of study intervention, every attempt', 'should be made to perform repeat assessments until the values return to normal or', 'baseline or if a new baseline is established as determined by the investigator.', 'Laboratory tests for hematology, chemistry, and others are specified within the Visit', 'Requirements in Section 6.1.5.', 'Laboratory tests for screening should be performed within 7 days prior to the first dose of', 'treatment. After Cycle 1, pre-dose laboratory procedures can be conducted up to 24 hours', 'prior to dosing. Results must be reviewed by the Investigator or qualified designee and found', 'to be acceptable prior to each dose of study treatment.', '6.1.4 Other Procedures', '6.1.4.1 Withdrawal/Discontinuation', 'Participants who withdraw prior to completion of the trial should be encouraged to complete all', 'applicable activities scheduled for the final study visit at the time of withdrawal. Any AEs that', 'are present at the time of withdrawal should be followed in accordance with the safety', 'requirements outlined in Section 6.2.', '6.1.4.2 Withdrawal from Translational Research / Future Biomedical Research', 'Participants may withdraw their consent for future biomedical research. Participants may', 'withdraw consent at any time by contacting the investigator. The investigator will inform the', 'Sponsor. It is the responsibility of the investigator to subsequently inform the participant of', 'completion of withdrawal. Any analyses in progress at the time of request for withdrawal or', 'already performed prior to the request for withdrawal being received will continue to be used', 'as part of the overall research study data and results. No new analyses should be generated', 'after the request is received.', 'In', 'the event that the specimens have been completely anonymized, there will be no link', \"between the participant's personal information and their specimens. In this situation, the\", 'request for specimen withdrawal cannot be processed.', 'Confidential', 'Page 47 of 79']\n\n###\n\n", "completion": "END"}